A study published in Nature Medicine identifies markedly elevated CAR T cell persistence as a distinguishing feature of immune effector cell-associated enterocolitis, offering new avenues for earlier diagnosis and improved patient monitoring following ciltacabtagene autoleucel therapy.  

shutterstock_2790952495

Patients with multiple myeloma who develop a serious gastrointestinal complication following chimeric antigen receptor (CAR) T-cell therapy have significantly higher levels of CAR T cells persisting in their bloodstream, according to new research.

The study, led by researchers at The University of Texas MD Anderson Cancer Center and published in Nature Medicine, found that patients experiencing immune effector cell-associated enterocolitis (IEC-EC) had more than 100 times the average level of long-term CAR T cell persistence compared with those who did not develop the condition.  

The findings could help clinicians recognise the complication earlier and identify patients who may benefit from closer monitoring following treatment.

Investigating a serious gastrointestinal complication

IEC-EC is a rare but potentially life-threatening complication of CAR T-cell therapy, characterised by persistent diarrhoea and gastrointestinal inflammation. It can lead to prolonged hospitalisation, the need for intensive nutritional support and an increased risk of death.

Researchers examined nine cases of IEC-EC among 158 patients with multiple myeloma who received the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel). Among this cohort, Approximately 5 percent of patients developed the condition.  

Analysis revealed that those affected had substantially higher levels of CAR T cells remaining in their blood long after treatment than patients who did not experience IEC-EC.

“Our study found that IEC-EC is not just inflammation of the gastrointestinal tract, but it is a distinct CAR T-cell therapy-driven immune cell disorder,” said corresponding author Mark Hamilton, Assistant Professor of Lymphoma and Myeloma at MD Anderson.

The researchers also examined tissue samples from affected patients, finding that CAR T cells had accumulated in the digestive tract. Their presence appeared to drive ongoing inflammation and tissue damage, suggesting that prolonged immune-cell activity may contribute to the development of the complication.

Improving diagnosis and patient monitoring

CAR T cell therapies have transformed treatment options for multiple myeloma, but understanding and managing serious side effects remains an important challenge.

The researchers suggest that measuring CAR T cell persistence could help identify patients at increased risk of IEC-EC, potentially allowing clinicians to intervene before symptoms become severe.   

Tissue analysis may also provide a route to faster diagnosis. The team highlighted endoscopic examination of the duodenum, the upper section of the small intestine, alongside testing for CAR T cells in tissue samples as potentially useful approaches for patients presenting with gastrointestinal symptoms.

“By understanding the biology behind this complication, we can improve recognition of the syndrome and develop more effective strategies to monitor and treat patients,” Hamilton said. 

Further research needed

Although the findings provide insight into the biological mechanisms underlying IEC-EC, more research will need to be undertaken to establish why some patients experience prolonged CAR T cell persistence and develop the complication while others do not.

The researchers also need to determine how best to prevent or manage IEC-EC and whether monitoring CAR T-cell levels could reliably predict which patients will develop it.

As the use of CAR T-cell therapies expands, understanding uncommon but potentially severe toxicities will be increasingly important for improving patient care and ensuring that the benefits of these treatments can be delivered as safely as possible.